Macrophage Imaging in Central Nervous System and in Carotid Atherosclerotic Plaque Using Ultrasmall Superparamagnetic Iron Oxide in Magnetic Resonance Imaging
暂无分享,去创建一个
Bruno Brochet | Klaus G. Petry | Vincent Dousset | Andreas Saleh | Rikin Trivedi | M. Rausch | J. Le Bas | V. Dousset | K. Petry | B. Brochet | D. Balériaux | C. Corot | E. Blezer | R. Trivedi | Claire Corot | Cornelia Jonkmanns | Martin Rausch | Paula Foster-Gareau | Jean-François Le Bas | Paula Foster-Gareau | Erwin Blezer | Danièle Balériaux | Sophile Gaillard | A. Saleh | C. Jonkmanns | S. Gaillard
[1] R Weissleder,et al. Magnetically labeled cells can be detected by MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.
[2] Hong Wang,et al. Investigation of Mechanisms Influencing the Accumulation of Ultrasmall Superparamagnetic Iron Oxide Particles in Lymph Nodes , 1995, Investigative radiology.
[3] J A Frank,et al. Frequency dependence of MR relaxation times II. Iron oxides , 1993, Journal of magnetic resonance imaging : JMRI.
[4] C. Corot,et al. Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. , 1996, Academic radiology.
[5] M. E. Kooi,et al. Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.
[6] J. Debatin,et al. Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits , 2001, Circulation.
[7] Wolfgang Ebert,et al. Tissue-specific MR contrast agents. , 2003, European journal of radiology.
[8] M. Taupitz,et al. In Vitro Characterization of Two Different Ultrasmall Iron Oxide Particles for Magnetic Resonance Cell Tracking , 2002, Investigative radiology.
[9] R Weissleder,et al. Improved delineation of human brain tumors on MR images using a long‐circulating, superparamagnetic iron oxide agent , 1999, Journal of magnetic resonance imaging : JMRI.
[10] S. Schmitz,et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. , 2000, Investigative radiology.
[11] B. Hamm,et al. Phase I Clinical Evaluation of Citrate-coated Monocrystalline Very Small Superparamagnetic Iron Oxide Particles as a New Contrast Medium for Magnetic Resonance Imaging , 2004, Investigative radiology.
[12] James I. Cohen,et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. , 2002, AJNR. American journal of neuroradiology.
[13] J C Gore,et al. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat. , 1990, Investigative radiology.
[14] P. Jacobs,et al. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.
[15] Bernd Hamm,et al. Monomer-Coated Very Small Superparamagnetic Iron Oxide Particles as Contrast Medium for Magnetic Resonance Imaging: Preclinical In Vivo Characterization , 2002, Investigative radiology.
[16] M. Heller,et al. Characterization of Ultrasmall, Paramagnetic Magnetite Particles as Superparamagnetic Contrast Agents in MRI , 2000 .
[17] M. Rausch,et al. Dynamic patterns of USPIO enhancement can be observed in macrophages after ischemic brain damage , 2001, Magnetic resonance in medicine.
[18] W. Heindel,et al. First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: Phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. , 2002, Academic radiology.
[19] Michael Schroeter,et al. Inflammation and glial responses in ischemic brain lesions , 1998, Progress in Neurobiology.
[20] J. Caillé,et al. Assessment by MRI of brain infiltration by peripheral blood macrophages in anti-VLA-4 antibody treatment of experimental autoimmune encephalomyelitis , 2003 .
[21] B Hamm,et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles , 2001, Journal of magnetic resonance imaging : JMRI.
[22] G Le Duc,et al. Use of T2‐weighted susceptibility contrast MRI for mapping the blood volume in the glioma‐bearing rat brain , 1999, Magnetic resonance in medicine.
[23] B. V. Beers,et al. Les oxydes de fer comme agents de contraste en IRM hépatique. , 1995 .
[24] T. Skotland,et al. In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging. , 2002, Journal of pharmaceutical and biomedical analysis.
[25] J. Bulte,et al. Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION‐46L enhanced in vivo MRI: Early histopathological correlation , 1998, Journal of Neuroscience Research.
[26] New MRI Contrast Agent for Labeling of Tumor-Associated Macrophages that Stimulate Tumor Angiogenesis , 2000 .
[27] R. Weissleder,et al. Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages , 1997, Journal of magnetic resonance imaging : JMRI.
[28] V. Fuster,et al. Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.
[29] A. Bjørnerud,et al. NC100150 injection, a preparation of optimized iron oxide nanoparticles for positive‐contrast MR angiography , 2000, Journal of magnetic resonance imaging : JMRI.
[30] M. Naghavi,et al. Superparamagnetic Iron Oxide–Based Method for Quantifying Recruitment of Monocytes to Mouse Atherosclerotic Lesions In Vivo: Enhancement by Tissue Necrosis Factor-&agr;, Interleukin-1&bgr;, and Interferon-&ggr; , 2003, Circulation.
[31] B Quesson,et al. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance , 1999, Magnetic resonance in medicine.
[32] Y Usson,et al. In vivo assessment of tumoral angiogenesis , 2004, Magnetic resonance in medicine.
[33] R Weissleder,et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.
[34] M. Rausch,et al. MRI‐based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE , 2003, Magnetic resonance in medicine.
[35] Urs O. Häfeli,et al. Scientific and clinical applications of magnetic carriers , 1997 .
[36] B. Bonnemain,et al. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. , 1998, Journal of drug targeting.
[37] G. Frija,et al. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. , 1993, Magnetic resonance imaging.
[38] Andreas Saleh,et al. In vivo MRI of brain in ̄ ammation in human ischaemic stroke , 2004 .
[39] C Delalande,et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. , 1999, AJNR. American journal of neuroradiology.
[40] A. Roch,et al. Transverse relaxivity of particulate MRI contrast media: From theories to experiments , 1991, Magnetic resonance in medicine.
[41] Isabelle Raynal,et al. Macrophage Endocytosis of Superparamagnetic Iron Oxide Nanoparticles: Mechanisms and Comparison of Ferumoxides and Ferumoxtran-10 , 2004, Investigative radiology.